Showing results (1681-1690 of 1,749) with videos related to

Sort By:
Pageof 175
European Journal of Clinical Nutrition|November 4, 2010
Biogenic amines in fermented foodsG Spano, P Russo, A Lonvaud-Funel, et al.
International Journal for Parasitology|May 21, 2019
The relationship between the presence of antibodies and direct detection of Toxoplasma gondii in slaughtered calves and cattle in four European countriesM Opsteegh, F Spano, D Aubert, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
Molecules (Basel, Switzerland)|April 25, 2020
Cannabis sativa L. Inflorescences from Monoecious Cultivars Grown in Central Italy: An Untargeted Chemical Characterization from Early Flowering to RipeningCinzia Ingallina, Anatoly P Sobolev, Simone Circi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2026
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancerS Rao, E Samalin-Scalzi, L Evesque, et al.
NPJ Precision Oncology|February 1, 2024
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastomaChiara Chiavelli, Malvina Prapa, Giulia Rovesti, et al.
Lancet (London, England)|June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 6, 2024
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cellsAngela Filograna, Stefano De Tito, Matteo Lo Monte, et al.
Science Advances|July 24, 2026
Molecular mechanism of CtBP1-S/BARS-driven membrane fission and its cellular control by metabolic ligandsStefano De Tito, Angela Filograna, Mikhail A Zhukovsky, et al.
Pageof 175